Pro-Pharmaceuticals, Inc. (AMEX: PRW), a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, has issued an open letter to shareholders from Theodore D. Zucconi, Ph.D., President of the Company.
[read full story]